Study preparations have been completed and necessary permits obtained.

Data from the first patient(s) expected in Q1/2024.

Tenboron is a showcase company in this year’s LSX Nordic Congress which takes place in Copenhagen, Denmark on October 10-11.

The Finnish Medicines Agency Fimea has approved Tenboron’s Phase I clinical trial application.
The study will be conducted at the Helsinki University Hospital.
Preparations for study initiation are underway.